Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Enolio 10 micrograms / ml Oral Solution
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Liothyronine sodium may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for The active substance of Enolio is liothyronine sodium which is called liothyronine in this leaflet. Liothyronine is a form of thyroxine which is quick acting and long lasting. Thyroxine is a hormone produced by the thyroid gland in the neck which controls many body functions. Liothyronine is used to:
- treat some of the more severe conditions in which the thyroid does not produce enough thyroxine.
- balance the effect of medicines used to treat an overactive thyroid.
What you need to know before you take it
e Enolio Do not take Enolio if you:
- are allergic to liothyronine or any of the other ingredients of this medicine (listed in section 6)
- have angina (chest pain when exercising) or conditions affecting your heart or circulation
- are suffering from thyrotoxicosis (condition due to over activity of the thyroid gland). Talk to your doctor before you take this medicine if any of the above apply to you. Warnings and Precautions Talk to your doctor or pharmacist before taking Enolio if you:
- are suffering from diabetes. Enolio may raise blood sugar levels
- are suffering from a condition called myxoedema (which can happen when you have a problem with your thyroid gland) which makes your skin look swollen and dry
- are elderly (65 years or over)
- have suffered from low levels of thyroid hormone in your body for a long time, as this may affect how your adrenal glands work. You may be given additional medication (corticosteroids) if this is the case
- are suffering from any heart problems
- have increased blood pressure
- suffer from increased heart rate, sleeplessness, loose watery stools (suggesting increased metabolism) on starting treatment. In this case a dose reduction may be needed
- are starting treatment, as an ECG test (a recording of the electrical activity of your heart) will be valuable
- are pregnant or breast-feeding.
If you are about to undergo laboratory testing for monitoring your thyroid hormone levels, you must inform your doctor and/or the laboratory personnel if you are taking or have recently taken biotin (also known as vitamin H, vitamin B7 or vitamin B8). Biotin may affect the results of your laboratory tests. Depending on the test, the results may be falsely high or falsely low due to biotin. Your doctor may ask you to stop taking biotin before performing laboratory tests. You should also be aware that other products that you may take, such as multivitamins or supplements for hair, skin and nails could also contain biotin. This could affect the results of laboratory tests. Please inform your doctor and/or the laboratory personnel, if you are taking such products (see section 'Other medicines and Enolio'). Other medicines and Enolio Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Enolio may affect or be affected by the following medicines:
- Anticoagulants (e.g. warfarin) used to thin the blood and prevent blood clots
- Anticonvulsants (e.g. carbamazepine or phenytoin) used to prevent fits
- Insulin and other treatments for diabetes
- Medicines called cardiac glycosides (e.g. digoxin) used to treat heart conditions such as heart failure
- Tricyclic antidepressants (e.g. amitriptyline / imipramine) used to treat depression
- Colestyramine / colestipol which reduce the level of cholesterol (fats) in the blood
- Oral contraceptives ('the pill')
- Amiodarone, used to treat irregular heart beats
- Barbiturates, used to induce sleep and decrease anxiety
- Primidone, used for seizures or fits If you are taking or have recently taken biotin, you must inform your doctor and/or the laboratory personnel when you are about to undergo laboratory testing for monitoring your thyroid hormone levels. Biotin may affect the results of your laboratory tests (see section 'Warnings and Precautions'). Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. The decision on whether it is best to take Enolio during pregnancy or breast-feeding will be made during discussions between you and your doctor. Driving and using machines Enolio should not interfere with your ability to drive or use machinery. Enolio contains sodium methyl parahydroxybenzoate (E 219) which may cause allergic reactions (possibly delayed). This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.
How to take it
Enolio Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is as follows: Adults: The dose will depend upon your condition, ranging from 1 ml (10 micrograms) to 6 ml (60 micrograms) daily in divided doses. Children and elderly: The dose may be started at 0.5 ml (5 micrograms) a day. Your doctor will monitor your thyroid function regularly to make sure that you are given the right dose for your condition. Method of Administration For oral administration. You should take the product with water. A 5 ml graduated oral syringe with intermediate graduations of 0.25 ml is provided with your medicine.
1
1. Open the bottle and insert the syringe into the adapter.
2. Turn the bottle upside down and while holding the syringe in place, gently pull the plunger down to draw out the medicine to the correct mark for your dose. 3. If any bubbles appear in the syringe, keep the bottle upside down, slowly push the plunger part way back into the bottle and then pull it out again. Repeat until there are no bubbles in the syringe.
2
3
4
4. Turn the bottle upright and carefully remove the filled syringe from the adaptor using gentle twisting.
5. Insert the syringe tip into your mouth and press the plunger slowly to release the medicine. Repeat steps 2 to 5 as needed to achieve the required dose.
Seek urgent medical advice if you experience the following side effects:
- An allergic reaction such as rash, itching or oedema (swelling / abnormal accumulation of body fluid)
- Angina pain (pain in the chest when exercising), irregular, thumping or fast heart beats. Seek urgent advice from your doctor if you experience these heart-related symptoms. This may be a sign that your dose of liothyronine needs to be reduced. You must not stop or reduce the amount of Enolio you are taking without consulting with your doctor first. Other side effects you could experience (frequency cannot be estimated from the available data) are:
- Vomiting (being sick)
- Insomnia (sleeplessness)
- Fever
- Intolerance to heat
- Tremor (involuntary, rhythmic muscle movements)
- Muscle cramps or weakness
- Diarrhoea
- Restlessness or excitability
- Headache
- Flushing
- Sweating
- Loss of weight Additional side effects in children
- Temporary loss of hair (frequency not known)
5
6
6. Replace the bottle cap after use, leaving the adaptor in place.
These effects normally mean the dose of Enolio needs changing. You should talk with your doctor if they occur. The effects usually go away when the dose has been changed. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Marketing Authorisation Holder Eclosix Ltd 329 Upper Fourth Street Milton Keynes MK9 1EH United Kingdom
Manufacturer Labomed Pharmaceutical Company SA 84 Ioannou Metaxa str. Koropi, Attica, 19441 Greece
This leaflet was last revised in November 2025
How to store it
Enolio Keep this medicine out of the sight and reach of children.
Wash the syringe with water after each use and allow it to dry completely before you next use it. For infants and smaller children, drug administration can be performed by an adult using the above instructions. Be sure to press the plunger slowly to ensure that the child can swallow the solution easily and does not choke. You should give your child a drink of water to help wash the medicine down. This medicine can be administered via a medium or large gastric, duodenal or nasal feeding tube if required. The tube should be rinsed twice with at least 10 ml of water following administration.
Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP. The expiry date refers to the last day of that month. Store in the original package in order to protect from light. Do not use your medicine if you notice that the bottle is damaged. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. Recycle the empty packaging where possible.
Contents of the pack and other information
If you take more Enolio than you should This may cause agitation, confusion, headache, sweating and a rapid pulse. If you take more of this medicine than you should contact your doctor or nearest hospital casualty department as soon as possible. Take the bottle and this leaflet with you so the medical staff will know what you have taken.
What Enolio contains
- The active substance is liothyronine sodium. Each 1 ml of Enolio contains 10 micrograms of liothyronine sodium.
- The other ingredients are glycerol, citric acid monohydrate, sodium citrate, sodium methyl parahydroxybenzoate (E 219), sodium hydroxide and purified water.
If you forget to take Enolio Take the next dose at the correct time and then go on as before. It is important, in order for your medicine to work, that doses are not forgotten. Do not take a double dose to make up for a forgotten dose.
What Enolio looks like and contents of the pack Enolio is a clear, colourless solution supplied in amber glass bottles with a polypropylene child-resistant, tamper evident cap fitted with a polyethylene syringe adaptor. Each bottle contains 50 ml or 100 ml of Enolio. Not all pack sizes may be marketed. The carton also contains a 5 ml polypropylene oral syringe with graduations of 0.25 ml.
If you stop taking Enolio Do not stop taking Enolio unless your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Frequently asked questions about Enolio 10 micrograms / ml Oral Solution
How do I take Enolio 10 micrograms / ml Oral Solution?
Enolio 10 micrograms / ml Oral Solution comes as oral solution containing 10mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Enolio 10 micrograms / ml Oral Solution?
The active substance in Enolio 10 micrograms / ml Oral Solution is liothyronine sodium.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Enolio 10 micrograms / ml Oral Solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Enolio 10 micrograms / ml Oral Solution without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: liothyronine sodium
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Liothyronine sodium is indicated in adults and children for the treatment of coma of myxoedema, the management of severe chronic thyroid deficiency and hypothyroid states occurring in the treatment of thyrotoxicosis.
Liothyronine sodium can also be used in the treatment of thyrotoxicosis as an adjunct to carbimazole to prevent sub-clinical hypothyroidism developing during treatment.
Liothyronine sodium may be preferred for treating severe and acute hypothyroid states because of its rapid and more potent effect, but thyroxine sodium is normally the drug of choice for routine replacement therapy.
4.2. Posology and method of administration
Posology
Adults:
Starting dose of 1 ml (10 micrograms) or 2 ml (20 micrograms) every 8 hours, increasing after one week, if necessary, to the usual recommended daily dose of 6 ml (60 micrograms) in two or three divided doses.
Myxoedema Coma:
6 ml (60 micrograms) given by stomach tube, then 2 ml (20 micrograms) every 8 hours. It is more usual to start treatment with intravenous liothyronine.
Adjunct to carbimazole treatment of thyrotoxicosis:
2 ml (20 micrograms) every 8 hours.
Elderly:
0.5 ml (5 micrograms) daily
Paediatric population:
0.5 ml (5 micrograms) daily
Method of administration
Oral use. This medicinal product should be taken with water.
If necessary, this medicinal product can be administered via a gastric, duodenal or nasal feeding tube (see section 6.6). Rinse the tube twice with at least 10 ml of water following administration.
4.3. Contraindications
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Patients with angina of effort or cardiovascular diseases and thyrotoxicosis.
4.4. Special warnings and precautions for use
In severe and prolonged hypothyroidism, adrenocortical activity may be decreased. When thyroid replacement therapy is started, metabolism increases more than adrenocortical activity and this can lead to adrenocortical insufficiency requiring supplemental adrenocortical steroids.
Liothyronine sodium rather than levothyroxine would be the replacement therapy of choice during block and replace treatment of thyrotoxicosis with propylthiouracil (PTU) due to the inhibition by PTU of the peripheral conversion of T4 to T3
Liothyronine sodium treatment may result in an increase in insulin or anti-diabetic drug requirements. Care is required for patients with diabetes mellitus and diabetes insipidus.
Panhypopituitarism or predisposition to adrenal insufficiency (initiate corticosteroid therapy before starting liothyronine sodium), pregnancy and breast-feeding (see section 4.6).
In myxoedema, care must be taken to avoid imposing excessive burden on cardiac muscle affected by prolonged severe thyroid depletion. Particular care is needed in the elderly who have a greater risk of occult cardiovascular disease. Baseline ECG is recommended prior to commencement of liothyronine treatment in order to detect changes consistent with ischaemia. Patients should undergo cardiovascular monitoring, including periodic ECGs, during liothyronine treatment. Liothyronine sodium is contraindicated in established myocardial ischaemia (see section 4.3) in which case, levothyroxine, with cautious dose escalation, is recommended instead.
If metabolism increases too rapidly (causing diarrhoea, nervousness, rapid pulse, insomnia, tremors and sometimes anginal pain where there is latent myocardial ischaemia), reduce dose or withhold for 1-2 days and start again at a lower dose.
TSH levels should be monitored during treatment to reduce the risk of over- or undertreatment. The risks of over-treatment include atrial fibrillation, osteoporosis and bone fractures.
Interference with laboratory tests:
Biotin may interfere with thyroid immunoassays that are based on a biotin / streptavidin interaction, leading to either falsely decreased or falsely increased test results. The risk of interference increases with higher doses of biotin.
When interpreting results of laboratory tests, possible biotin interference has to be taken into consideration, especially if a lack of coherence with the clinical presentation is observed.
For patients taking biotin-containing products, laboratory personnel should be informed when a thyroid function test is requested. Alternative tests not susceptible to biotin interference should be used, if available. (see section 4.5),
This medicinal product contains sodium methyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).
This medicine contains less than 1mmol sodium (23mg) per 5ml dose, that is to say essentially 'sodium-free'.
4.5. Interaction with other medicinal products and other forms of interaction
Liothyronine sodium therapy may potentiate the action of anticoagulants. Phenytoin levels may be increased by liothyronine sodium. Anticonvulsants, such as carbamazepine and phenytoin enhance the metabolism of thyroid hormones and may displace thyroid hormones from plasma proteins. Initiation or discontinuation of anticonvulsant therapy may alter liothyronine sodium dose requirements.
If co-administered with cardiac glycosides, adjustment of the dosage of the cardiac glycoside may be necessary. Colestyramine and colestipol given concurrently reduces gastrointestinal absorption of liothyronine sodium.
Liothyronine sodium raises blood sugar levels and this may upset the stability of patients receiving antidiabetic agents.
Liothyronine sodium increases receptor sensitivity to catecholamines thus accelerating the response to tricyclic antidepressants. A number of drugs may affect thyroid function tests and this should be borne in mind when monitoring patients on liothyronine therapy.
Co-administration of oral contraceptives may result in an increased dosage requirement of liothyronine sodium.
Amiodarone may inhibit the deiodination of thyroxine to triiodothyronine resulting in a decreased concentration of triiodothyronine with a rise in the concentration of inactive reverse triiodothyronine.
As with other thyroid hormones, liothyronine sodium may enhance effects of amitriptyline and effects of imipramine.
Metabolism of thyroid hormones accelerated by barbiturates and primidone (may increase requirements for thyroid hormones in hypothyroidism).
Requirements for thyroid hormones in hypothyroidism may be increased by oestrogens.
Interference with laboratory tests:
Biotin may interfere with thyroid immunoassays that are based on a biotin / streptavidin interaction, leading to either falsely decreased or falsely increased test results (see section 4.4).
4.6. Fertility, pregnancy and lactation
Pregnancy
Safety during pregnancy is not known. The risk of foetal congenital abnormalities should be weighed against the risk to the foetus of untreated maternal hypothyroidism.
Breast-feeding
Liothyronine sodium is excreted into breast milk in low concentrations.
This may interfere with neonatal screening programmes.
Fertility
No human or animal data on the effect of the active substance liothyronine sodium on fertility are available.
4.7. Effects on ability to drive and use machines
Liothyronine sodium has no or negligible influence on the ability to drive and use machines.
4.8. Undesirable effects
The following effects are indicative of excessive dosage and usually disappear on reduction of dosage or withdrawal of treatment for a day or two.
The undesirable effects are listed below by organ class and the following frequency convention:
Not known (frequency cannot be estimated from the available data)
System Organ Class
Frequency
Adverse events
Immune system disorders
Not known
Hypersensitivity reactions including rash, pruritus and oedema also reported.
Metabolism and nutrition disorders
Not known
Excessive loss of weight
Psychiatric disorders
Not known
Restlessness, excitability, insomnia
Nervous System disorders
Not known
Headache, tremor
Cardiac disorders
Not known
Anginal pain, cardiac arrhythmias, palpitations, tachycardia
Vascular disorders
Not known
Flushing
Gastrointestinal disorders
Not known
Diarrhoea, vomiting
Skin and subcutaneous tissue disorders
Not known
Sweating
Musculoskeletal and connective tissue disorders
Not known
Muscle cramps, muscular weakness
General disorders and administration site conditions
Not known
Fever, flushing and heat intolerance
Paediatric population:
Transient hair loss in children (Not Known)
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Symptoms:
If patient is seen within a few hours of overdosage: gastric lavage or emesis.
There may be exaggeration of the side effects as well as agitation, confusion, irritability, hyperactivity, headache, sweating, mydriasis, tachycardia, arrhythmias, tachypnoea, pyrexia, increased bowel movements and convulsions.
Management:
Treatment is symptomatic. Tachycardia in adults may be controlled with 40mg propanolol every 6 hours.
🇷🇴 Known in Romania as
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Liothyronine sodium. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
- NOVOTHYRAL 100/20 micrograme prescription partial — not the same combinationCOMBINATII (LEVOTHYROXINUM+LIOTHYRONINUM) · taken by mouth
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
🇵🇱 Known in Poland as
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Not the same combination. This medicine contains Liothyronine sodium. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
- Novothyral partial — not the same combinationLevothyroxinum natricum + Liothyroninum natricum · taken by mouth
- Novothyral 75 partial — not the same combinationLevothyroxinum natricum + Liothyroninum natricum · taken by mouth
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
💬 Ask about this leaflet
Ask anything about Enolio 10 micrograms / ml Oral Solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
Medicines containing Liothyronine sodium
- Liothyronine sodium 10 micrograms Hard Capsules
- Liothyronine Sodium 10 micrograms Tablets
- Liothyronine sodium 20 micrograms Hard Capsules
- Liothyronine Sodium 20 micrograms Powder for Solution for Injection
- Liothyronine Sodium 20 micrograms Tablets
- Liothyronine sodium 5 micrograms Hard Capsules
- Liothyronine Sodium 5 micrograms Tablets
- Liothyronine Sodium BP 20micrograms Tablets